Background-Chronic kidney disease is a risk factor for cardiovascular disease, increasing all-cause mortality. Some evidence suggests that endothelial dysfunction is present in the early stages of renal insufficiency, but no data exist about its possible role in the progression of renal disease. Thus, we prospectively evaluated the effect of endothelial function on estimated glomerular filtration rate (eGFR) in essential hypertension. Methods and Results-We enrolled 500 never-treated uncomplicated hypertensive subjects with serum creatinine Յ1.5 mg/dL. Endothelial function was measured by strain-gauge plethysmography during intra-arterial infusion of acetylcholine and sodium nitroprusside. 
R enal function decline, estimated by glomerular filtration rate (GFR), is associated with increased cardiovascular morbidity and mortality in the general population and in various patient settings, [1] [2] [3] and mild to moderate renal insufficiency has emerged as a major public and clinical health problem. Population-based studies 4 and secondary analyses of intervention studies in both hypertensive patients 5 and selected patients at high cardiovascular risk 6 have shown that classic risk factors such as hypertension, diabetes mellitus, hyperlipidemia, smoking, and overweight/obesity represent major correlates of renal dysfunction.
Clinical Perspective on p 384
Physiologically, the endothelium exerts certain vasoprotective effects, suppressing the adhesion of leukocytes and monocytes, inhibiting both the migration and proliferation of vascular smooth muscle cells and platelet aggregation, [7] [8] [9] all factors that operate in the appearance and progression of atherosclerosis. Conversely, a dysfunctional endothelium loses its ability to protect the vascular system by reducing its antiatherosclerotic and antithrombotic actions. Of interest, some studies have clearly demonstrated that endothelial dysfunction, evaluated in both coronary 10 -13 and forearm 14 vasculature, provides prognostic information for future clinical events. Finally, endothelial dysfunction has been demonstrated in patients with both traditional 14 -19 and emerging 20 -23 cardiovascular risk factors, all also associated with renal disease.
There is some evidence which suggests that endothelial dysfunction is already present in the early stages of renal insufficiency. 24, 25 In keeping with this, we previously demonstrated that an impaired endothelium-dependent vasodilatory response is associated with renal dysfunction in hypertensive patients, which suggests that systemic endothelial dysfunction is involved in mild to moderate renal insufficiency in patients with uncomplicated essential hyperten-sion. 26 However, information is lacking about the possible role of endothelial function in the progression of renal disease. Thus, we designed the present study to prospectively assess the role of endothelial function, evaluated by straingauge plethysmography, on estimated GFR (eGFR) decline in a group of well-characterized hypertensive patients.
Methods

Patients
We recruited 500 hypertensive outpatients (256 men and 244 women; mean age 47.2Ϯ11.0 years; all white) selected from a population of Ϸ3800 individuals referred to the hypertension clinic of the University Hospital of Catanzaro between September 1994 and January 2004. At the time of the first evaluation, patients had newly diagnosed essential hypertension with a serum creatinine Յ1.5 mg/dL, without proteinuria on the dipstick test, and had never been treated previously. None of the patients had a history or clinical evidence of angina, myocardial infarction, valvular heart disease, diabetes mellitus, hypercholesterolemia, peripheral vascular disease, coagulopathy, or any disease predisposing to vasculitis or Raynaud's phenomenon. Secondary forms of hypertension were excluded by systematic testing according to a standard clinical protocol, which included measurement of plasma renin activity, aldosterone, Doppler studies of the renal arteries, and/or renal scintigraphy or renal angiography. At the time of the first evaluation, we performed routine blood tests, assessment of atherosclerosis risk factors, and evaluation of vascular function.
In accordance with the aim of the study, since March 2006, patients with at least 2 years of follow-up and free of cardiovascular diseases and/or events and metabolic disorders were reevaluated specifically for renal function and cardiovascular risk factors. The local ethics committee approved the study, and all participants gave written informed consent for all procedures.
Renal Function
Creatinine measurements were performed at baseline and at the end of follow-up by use of the Jaffe methodology and the uricaseperoxidase (uricase/POD; Boehringer Mannheim, Mannheim, Germany) method implemented in an auto-analyzer. Values of eGFR (mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 ) were calculated with the new equation proposed by investigators in the Chronic Kidney Disease Epidemiology (CKD-EPI) Collaboration. 27 This equation was developed from a cohort of patients that included both healthy individuals and individuals with chronic kidney disease and that was much larger than the Modification of Diet in Renal Disease study. We preferred this equation because it is more accurate in subjects with GFR Ͼ60 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 , which our patients were expected to have in light of the creatinine value being Ͻ1.5 mg/dL. 27 Reassessment of renal function was undertaken in all patients 92.3Ϯ36.2 months later (range 28 to 170 months). The annual rate of decline of eGFR (⌬eGFR per year) was determined by subtracting the eGFR value at reassessment from the eGFR at baseline and then dividing this value by the time interval in years between the 2 periods of evaluation for each subject.
Forearm Blood Flow Measurement
All studies were performed at 9 AM after an overnight fast with the subjects lying supine in a quiet, air-conditioned room (22°C to 24°C). The subjects were instructed to continue their regular diet and were asked to refrain from alcohol and smoking for 24 hours before the test. Forearm volume was determined by water displacement. Under local anesthesia and sterile conditions, a 20-gauge polyethylene catheter (Vasculon 2, Baxter Healthcare, Deerfield, Ill) was inserted into the brachial artery of the nondominant arm of each subject for evaluation of blood pressure (BP; Baxter Healthcare) and for drug infusion. This arm was elevated slightly above the right atrium, and a mercury-filled Silastic strain gauge was placed on the widest part of the forearm. The strain gauge was connected to a plethysmograph (model EC-4, DE Hokanson, Issaquah, Wash) calibrated to measure the percent change in volume; this was connected to a chart recorder to obtain forearm blood flow (FBF) measurements. A cuff placed on the upper arm was inflated to 40 mm Hg with a rapid cuff inflator (model E-10, DE Hokanson) to exclude venous outflow from the extremity. The antecubital vein of the opposite arm was cannulated. FBF was measured as the slope of the change in forearm volume; the mean of at least 3 measurements was obtained at each time point.
Vascular Function
We used the protocol described by Panza et al 15 and subsequently employed by us. 14, 22, 23, 26 Standardization of the technique in our laboratory was described previously. 14 All patients underwent measurement of FBF and BP during intra-arterial infusion of saline, acetylcholine (ACh), and sodium nitroprusside (SNP) at increasing doses. All participants rested 30 minutes after artery cannulation to reach a stable baseline before data collection; measurements of FBF and vascular resistance (VR) were repeated every 5 minutes until stable. Endothelium-dependent and -independent vasodilation were assessed by a dose-response curve to intra-arterial ACh infusions (7.5, 15, and 30 g ⅐ mL Ϫ1 ⅐ min Ϫ1 , each for 5 minutes) and SNP infusions (0.8, 1.6, and 3.2 g ⅐ mL Ϫ1 ⅐ min Ϫ1 , each for 5 minutes), respectively. The sequence of administration of ACh and SNP was randomized to avoid any bias related to the order of drug infusion. ACh (Sigma, Milan, Italy) was diluted with saline immediately before infusion. SNP (Malesci, Florence, Italy) was diluted in 5% glucose solution immediately before each infusion and protected from light with aluminum foil.
Statistical Analysis
The analysis was performed on the complete data set, and results were expressed as meanϮSD or as percent frequency. Comparisons between groups were made by paired or unpaired Student t test, 2 test, or test for linear trend across quartiles, as appropriate. Linear regression analysis was used to assess the relationship between baseline eGFR or annual rate of decline of eGFR and traditional risk factors (age, body mass index, systolic BP, cholesterol, smoking status, and fasting glucose) and ACh-stimulated FBF. Finally, we constructed multivariable models using ⌬eGFR as the dependent variable. Regression model results are presented as regression coefficients and their standard errors. For repeated measurements of eGFR, the relationship between FBF and renal function was assessed by a linear mixed model that included FBF and Framingham risk factors. A linear mixed model incorporates random effects to account for correlated observations on the same subject (that is, to model the dependence of eGFR at follow-up on eGFR at baseline). In 2-tailed tests, a value of PϽ0.05 was considered statistically significant. All calculations were made with a standard statistical package (SPSS for Windows version 12.0).
Results
Patients
All patients were evaluated periodically for clinical, biochemical, and cardiovascular measurements. Based on the maximal response to ACh, patients were grouped into quartiles of vasodilatory response from the lowest to the highest values. Demographic, clinical, and humoral data of the study population at baseline, stratified by quartiles of ACh-stimulated FBF, and at follow-up are reported in Table 1 . Patients in the upper quartile were younger, with a lower preponderance of males and a lower body mass index than patients in the other 3 quartiles. A linear variation among quartiles was observed in serum creatinine and eGFR. No significant difference was observed for smoking status, lipid profile, fasting glucose, BP, heart rate, basal FBF, or VR. Conversely, neither serum creatinine or eGFR was statistically different when patients were grouped according to maximal response to SNP.
To reduce clinic BP to Ͻ140/90 mm Hg, all patients were treated with standard lifestyle and pharmacological treatments; diuretics, ␤-blockers, angiotensin-converting enzyme inhibitors, calcium channel blockers, angiotensin II receptor antagonists, and ␣ 1 -blockers were used alone or in various combinations. Baseline systolic and diastolic BP values decreased from 149Ϯ17 and 91Ϯ12 mm Hg, respectively, to 134Ϯ12 and 80Ϯ8 mm Hg (PϽ0.001) at the time of the second evaluation.
Vascular Function
Intra-arterial infusion of ACh caused a dose-dependent and significant (PϽ0.001) increase in FBF and a decrease in forearm VR. FBF increments from baseline with the 3 incremental doses of ACh were 1.8Ϯ1.6 (55%), 5.2Ϯ3.9 (158%), and 10.1Ϯ6.7 mL per 100 mL of tissue per minute (303%). At the highest dose of ACh (30 g/min), FBF increased to 13.5Ϯ6.7 mL ⅐ 100 mL tissue Ϫ1 tissue ⅐ min Ϫ1 , and VR decreased to 10.1Ϯ5.1 U. Intra-arterial infusion of ACh caused no changes in BP or heart rate values. From the lower to the upper quartile, the peak percent increase in FBF ranged from 116.4Ϯ36.7% to 552.4Ϯ150.5% (PϽ0.0001 by linear trend test; Table 1) .
Similarly, SNP infusion induced a significant (PϽ0.001) increase in FBF and a decrease in forearm VR. The FBF increments from baseline at the 3 incremental doses of SNP were 2.2Ϯ1.1 (70%), 5 Table 2 ).
Reduction of eGFR
The mean annual rate of decrease of eGFR was 1.49Ϯ1.65 mL ⅐ min Ϫ1 ⅐ 1.73 m
Ϫ2
, which was not statistically different in Figure we graphically report both the eGFR at baseline and at follow-up and ⌬eGFR values in the study population stratified by quartiles of AChstimulated FBF. The worst vasodilatory response to ACh was associated with both the lowest eGFR values at the end of follow-up and the highest annual rate of eGFR reduction. To test the theory that most renal function modifications are associated with endothelial function, we constructed a statistical model in which we also included the baseline eGFR values. This model also retained ACh-stimulated FBF as the most important covariate associated with renal function deterioration. Thus, FBF provides information on eGFR changes above and beyond that provided by baseline eGFR.
To test the association between change in eGFR and ACh-stimulated FBF after adjustment for other risk factors and concomitant antihypertensive treatment, we performed multiple regression analyses that included demographic and cardiovascular risk factors (model 1). As shown in Table 3 , systolic BP was the only significant factor related to change in eGFR. When we added the ACh-induced vasodilatory response (model 2), FBF and systolic BP were the only baseline covariates that remained significantly associated with a decrease in eGFR. On average, eGFR changed by 0.37 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 for each 100% change in FBF (PϽ0.001) and by 0.1 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 for each 10-mm Hg change in systolic BP (Pϭ0.032). The addition of mean changes, over the length of the follow-up period, in Framingham risk factors (model 3) did not substantially alter the results of the analysis. In a linear mixed model that adjusted for Framingham risk factors, only FBF and age were independent factors associated with eGFR (Table 4) . In this analysis, a 100% decrease in FBF was independently associated with a Ϫ2.8 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 decrease in eGFR.
Discussion
The present study provides, for the first time, a clinically relevant result, because we have demonstrated in a large cohort of well-characterized hypertensive patients that AChstimulated vasodilation is associated with a decline in eGFR independent of traditional cardiovascular risk factors. Even if the relationship between FBF and eGFR is expressed by a low correlation coefficient, we consider this association to be as clinically important as that documented between systolic BP and cardiac mass. This evidence contributes to improve Figure. eGFR and ⌬eGFR values in the study population stratified by quartiles of ACh-stimulated FBF. As seen, the lowest vasodilatory response to ACh was associated with both basal eGFR and the annual rate of eGFR reduction. In particular, a significant difference (PϽ0.001) was observed in ⌬eGFR values among quartiles, with the highest loss of eGFR annual rate in the quartile with the worst responsiveness to ACh at baseline. the stratification of global cardiovascular risk in hypertensive subjects, because renal insufficiency has been proposed as an independent predictor of cardiovascular disease and all-cause mortality. This has been demonstrated in several groups, particularly in the elderly and the general population, but also in selected patients with hypertension, myocardial infarction, or congestive heart failure. [1] [2] [3] [4] [5] [6] In keeping with this, the diagnosis of renal dysfunction should alert the practitioner to routinely assess renal function to correctly define the total burden of cardiovascular disease. However, despite the established association between chronic renal damage and cardiovascular disease, this risk is often not optimized for these patients in the community setting, because screening for chronic kidney disease is frequently limited to a measurement of serum creatinine, which does not accurately reflect GFR, the best indicator of renal function in healthy and diseased subjects. 28, 29 Several large prospective studies have demonstrated that even mild degrees of renal impairment may be associated with cardiovascular disease and mortality. [1] [2] [3] [4] [5] [6] In the Hoorn study, a decrease of 5 mL ⅐ min Ϫ1 ⅐ 1.73 m Ϫ2 in GFR was associated with a 22% increased risk for cardiovascular death after adjustment for traditional cardiovascular risk factors and previous cardiovascular disease. 30 The present study demonstrates that endothelial dysfunction is associated with renal function decline in a large group of hypertensive patients with normal or only mildly impaired baseline renal function, even though it cannot be excluded that eGFR reduction itself induces endothelial dysfunction, establishing a vicious circle which, if not interrupted, promotes the progression of both renal and vascular damage. In fact, even if chronic kidney disease is associated with several cardiovascular risk factors, such as hypertension, diabetes mellitus, hypercholesterolemia, and age, the excessive cardiovascular risk related to chronic kidney disease is not entirely explained by the clustering of traditional cardiovascular risk factors. This excessive risk may be explained, at least in part, by endothelial dysfunction and vascular inflammation, which are important and interrelated early steps in the atherosclerotic disease process. 9 Remarkably, the observation that vascular function was strongly associated with GFR decline suggests that systemic endothelial dysfunction represents an important physiopathological mechanism for the appearance and progression of mild renal dysfunction in hypertensive status.
Given that angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers are capable of slowing the progression of renal damage and improving endothelial dysfunction, [31] [32] [33] [34] it is possible that their renoprotective action is mediated, at least in part, by an amelioration of vascular damage. Together, these findings could lead to the possible prevention of end-stage renal disease, the saving of resources, improvements in quality of life, and reductions in cardiovascular events related to chronic kidney disease. 35 These considerations have clinical relevance, especially in patients similar to those of the present study population, who were young and had a recent diagnosis of hypertension.
Study Strengths and Limitations
The strength of this work is that the study population consisted of a large and carefully selected group of hypertensive patients. Another strength is the use of a minimally invasive measure of endothelial function that is more accurate than other noninvasive methods. Moreover, none of the participants had diabetes mellitus or overt cardiovascular disease, and at the time of the first evaluation, they were not taking any lipid-lowering or antihypertensive drugs.
The present findings were obtained in initially untreated hypertensive white subjects, so our results may not be extended to different racial groups or to subjects receiving antihypertensive treatment. The lack of assessment of serial changes in endothelial function over time may be another limitation. Although we used the newer CKD-EPI equation, which has demonstrated less bias at higher GFR values, in the present study, we did not have a direct measurement of GFR.
CLINICAL PERSPECTIVE
Endothelial dysfunction is associated with cardiovascular risk factors and with future cardiovascular events. In this study, we examined the relationship of endothelial dysfunction to the decline in renal function in patients with uncomplicated hypertension and a baseline serum creatinine of less than 1.5 mg/dL. Endothelial dysfunction was associated with a greater decline in renal function even after adjustment for the known adverse effects of elevated systolic blood pressure. These data suggest that endothelial dysfunction may exacerbate the decline in renal function in patients with hypertension and that therapies to improve endothelial function may help prevent the development of hypertensive kidney disease. Although not tested in the present study, the prevention of progressive renal disease in patients with hypertension may not only rely on intensive blood pressure control but also on other interventions known to improve endothelial function, such as lifestyle modification, treatment of dyslipidemia, and smoking cessation.
